A Phase II, Adaptive Trial Design Examining the Pharmacokinetic and Pharmacodynamic Effects of Modified Release Amphetamine (HLD100, Formulations B, C and E)) in Adolescents and Children With Attention-Deficit Hyperactivity Disorder (ADHD)
Clinical trial NCT01886469 · COMPLETED
Trial details
- NCT number
- NCT01886469
- Sponsor
- Ironshore Pharmaceuticals and Development, Inc
- Status
- COMPLETED
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2013-07-01
- Primary completion
- 2013-09-01
- Enrollment
- 22
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.